Amarin GAAP EPS of -$0.03 beats by $0.22, revenue of $72.74M beats by $18.98M
Source: SeekingAlpha
2025-07-30 07:02:54 ET
More on Amarin
- Amarin Is A Sell Despite The Large Cash Balance
- Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript
- Amarin Corporation plc 2025 Q1 - Results - Earnings Call Presentation
- Amarin Q2 2025 Earnings Preview
- Amarin inks licensing deal with Recordati for lead drug Vazkepa
Read the full article on Seeking Alpha
For further details see:
Amarin GAAP EPS of -$0.03 beats by $0.22, revenue of $72.74M beats by $18.98M
Amarin Corporation plc
NASDAQ: AMRN
AMRN Trading
-2.74% G/L:
$14.6957 Last:
7,384 Volume:
$15 Open:
AMRN Latest News
March 18, 2026 08:30:00 am
Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline
March 07, 2026 01:35:00 am
Here's Why I Wouldn't Touch Amarin With a 10?Foot Pole Given Its Patent and Competition Risks
AMRN Stock Data
$312,618,004
18,426,477
1.2%
30
N/A
Pharmaceuticals
Healthcare
IE
Dublin 2
